Phase diagrams map the properties of antiviral agents directed against hepatitis B virus core assembly

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1505-1508

  Li, Lichun ^a   Chirapu, Srinivas Reddy ^b   Finn, M G ^b   Zlotnick, Adam ^a  

^a INDIANA UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AT 130; CAPSID PROTEIN; DIMER; HEPATITIS B CORE ANTIGEN; HETEROARYLDIHYDROPYRIMIDINE 12; HETEROARYLDIHYDROPYRIMIDINE 13; POLYMER; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; STOICHIOMETRY; THERMODYNAMICS; VIRUS CAPSID;

ANTIVIRAL AGENTS; BENZAMIDES; BINDING SITES; CAPSID; CAPSID PROTEINS; HEPATITIS B VIRUS; KINETICS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PYRIMIDINES; THERMODYNAMICS; VIRAL CORE PROTEINS; VIRUS ASSEMBLY;

EID: 84874031889     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01766-12     Document Type: Article

References (33)

1. WHO. 2004. WHO position on the use of hepatitis B vaccines. Wkly Epidemiol. Rec. 28:255-263.
2. Matthews GV, Seaberg E, Dore GJ, Bowden S, Lewin SR, Sasadeusz J, Marks P, Goodman Z, Philp FH, Tang Y, Locarnini S, Thio CL. 2009. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS 23:1707-1715.
3. Nguyen T, Locarnini S. 2009. Hepatitis: monitoring drug therapy for hepatitis B-a global challenge? Nat. Rev. Gastroenterol. Hepatol. 6:565- 567.
4. Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137:1593-1608.
5. Committee on the Prevention and Control of Viral Hepatitis Infection, Institute of Medicine. 2010. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. The National Academies Press, Washington, DC.
6. Nassal M. 2008. Hepatitis B viruses: reverse transcription a different way. Virus Res. 134:235-249.
7. Seeger C, Zoulim F, Mason WS. 2007. Hepadnaviruses, p 2977-3029. In Knipe DM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
8. Nassal M. 1992. The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive- strand DNA synthesis but not for virus assembly. J. Virol. 66:4107- 4116.
9. Ricco R, Kanduc D. 2010. Hepatitis B virus and Homo sapiens proteomewide analysis: a profusion of viral peptide overlaps in neuron-specific human proteins. Biologics 4:75- 81.
10. Seeger C, Mason WS. 2000. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64:51- 68.
11. Steven AC, Conway JF, Cheng N, Watts NR, Belnap DM, Harris A, Stahl SJ, Wingfield PT. 2005. Structure, assembly, and antigenicity of hepatitis B virus capsid proteins. Adv. Virus Res. 64:125-164.
12. Ceres P, Stray SJ, Zlotnick A. 2004. Hepatitis B virus capsid assembly is enhanced by naturally occurring mutation F97L. J. Virol. 78:9538 -9543.
13. Prevelige PEJ. 1998. Inhibiting virus-capsid assembly by altering the polymerisation pathway. Trends Biotechnol. 16:61- 65.
14. Zlotnick A, Ceres P, Singh S, Johnson JM. 2002. A small molecule inhibits and misdirects assembly of hepatitis B virus capsids. J. Virol. 76: 4848-4854.
15. Zlotnick A, Mukhopadhyay S. 2011. Virus assembly, allostery and antivirals. Trends Microbiol. 19:14 -23.
16. Zlotnick A, Stray SJ. 2003. How does your virus grow? Understanding and interfering with virus assembly. Trends Biotechnol. 21:536 -542.
17. Bourne C, Lee S, Venkataiah B, Lee A, Korba B, Finn MG, Zlotnick A. 2008. Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle. J. Virol. 82:10262-10270.
18. Hacker HJ, Deres K, Mildenberger M, Schroder CH. 2003. Antivirals interacting with hepatitis B virus core protein and core mutations may misdirect capsid assembly in a similar fashion. Biochem. Pharmacol. 66: 2273-2279.
19. Katen SP, Chirapu SR, Finn MG, Zlotnick A. 2010. Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators. ACS Chem. Biol. 5:1125-1136.
20. Stray SJ, Bourne CR, Punna S, Lewis WG, Finn MG, Zlotnick A. 2005. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc. Natl. Acad. Sci. U. S. A. 102:8138-8143.
21. Stray SJ, Zlotnick A. 2006. BAY 41-4109 has multiple effects on hepatitis B virus capsid assembly. J. Mol. Recognit. 19:542-548.
22. Adamson CS, Freed EO. 2010. Novel approaches to inhibiting HIV-1 replication. Antiviral Res. 85:119 -141.
23. Kota S, Takahashi V, Ni F, Snyder JK, Strosberg AD. 2012. Direct binding of a hepatitis C virus inhibitor to the viral capsid protein. PLoS One 7:e32207. doi:10.1371/journal.pone.0032207.
24. Nangola S, Urvoas A, Valerio-Lepiniec M, Khamaikawin W, Sakkhachornphop S, Hong SS, Boulanger P, Minard P, Tayapiwatana C. 2012. Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein. Retrovirology 9:17. doi:10.1186/1742-4690-9-17.
25. Delaney WE, IV, Edwards R, Colledge D, Shaw T, Furman P, Painter G, Locarnini S. 2002. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob. Agents Chemother. 46:3057-3060.
26. Deres K, Schroder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, Kramer T, Niewohner U, Pleiss U, Stoltefuss J, Graef E, Koletzki D, Masantschek RN, Reimann A, Jaeger R, Gross R, Beckermann B, Schlemmer KH, Haebich D, Rubsamen-Waigmann H. 2003. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299:893- 896.
27. King RW, Ladner SK, Miller TJ, Zaifert K, Perni RB, Conway SC, Otto MJ. 1998. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)β-L- 2', 3'-dideoxy-3'-thiacytidine. Antimicrob. Agents Chemother. 42:3179- 3186.
28. Perni RB, Conway SC, Ladner SK, Zaifert K, Otto MJ, King RW. 2000. Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication. Bioorg. Med. Chem. Lett. 10:2687-2690.
29. Stoltefuss J, Goldmann S, Krämer T, Schlemmer K-H, Niewöhner U, Paessens A, Lottmann S, Deres K, Weber O. 1 October 1999. New dihydropyrimidine derivatives and their corresponding mesomers useful as antiviral agents. WO patent 9954326.
30. Bourne C, Finn MG, Zlotnick A. 2006. Global structural changes in hepatitis B capsids induced by the assembly effector HAP1. J. Virol. 80: 11055-11061.
31. Feld JJ, Colledge D, Sozzi V, Edwards R, Littlejohn M, Locarnini SA. 2007. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res. 76:168 -177.
32. Porterfield JZ, Zlotnick A. 2010. A simple and general method for determining the protein and nucleic acid content of viruses by UV absorbance. Virology 407:281-288.
33. Katen SP, Zlotnick A. 2009. Thermodynamics of virus capsid assembly. Methods Enzymol. 455:395- 417.